Should You Be Tempted By Yields At Royal Dutch Shell plc (8.6%), Ashmore Group plc (7.7%) & Medicx Fund Ltd. (6.9%)?

Are Royal Dutch Shell plc (LON:RDSA)(LON:RDSB), Ashmore Group plc (LON:ASHM) and Medicx Fund Ltd. (LON:MXF) high yield traps or genuine bargains? A look at sector-based or cyclical trends, dividend history and earnings outlooks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Income investors generally prefer stocks with higher dividend yields, but a very high yield is often seen as a warning sign that the dividend may soon be cut. A higher than average dividend yield is not always better, and so it is important to select high quality stocks with reliable cash flow generation. To distinguish between dividend traps and genuine bargains we should look out for sector-based or cyclical trends, dividend cover and the outlook for earnings.

With this in mind, should you buy Royal Dutch Shell (LSE: RDSA)(LSE: RDSB), Ashmore Group (LSE: ASHM) and MedicX Fund (LSE: MXF)?

Earnings slump

If we ignored Shell’s recent earnings slump, then the oil giant would look like an amazing dividend stock. The company has never cut its dividends since the end of the second world war, benefits from a 5-year average gross margin of nearly 17% and has very low levels of indebtedness.

Unfortunately, we can’t ignore Shell’s declining profitability, as the signs point to an uncertain future. Shell has already had to conserve cash by freezing its quarterly dividend at $0.47 per share and re-introduced its Scrip Dividend Programme in 2015. Low oil prices, which caused underlying annual earnings to fall 53% over the past year, is likely to persist for longer than expected and possibly fall to as low as $10 per barrel.

To finance the gap between operating cash flow and spending on capex and dividends, Shell has resorted to selling assets and raising new debt. Net gearing remains low, at 14.0%, compared to 12.2% last year. But, this has only been made possible by large-scale asset sales (which helped bring down oil production by 4% to 2.95m barrels of oil equivalent per day) and because Shell’s costly acquisition of BG Group has yet to be completed. The BG deal will do little to help Shell’s cash flow either, as BG’s annual free cash flow (before dividend payments) in 2015 was a negative $2.4bn.

So, unless oil prices rebound significantly, Shell’s 8.6% dividend yield does not seem sustainable for too much longer.

Massive outflows

Like its bigger rival Aberdeen Asset Management, Ashmore Group is suffering from massive fund outflows as investors cash out of investments in emerging markets. Assets under management have fallen 22.4% over the past year, as a result of a combination of investor outflows and declining asset values.

Net outflows have slowed recently, but there a few signs that a reversal will be soon be due. Fundamentals in emerging markets are beginning to look more attractive but investors are maintaining a cautious stance in fear of further interest rate hikes in the US and the constant stream of disappointing economic data.

With assets under management being regarded as an important indicator of future profits in the business, Ashmore’s long term earnings outlook is unimpressive. Analysts expect Ashmore will see earnings fall 23% in this year, and this should mean dividend cover is expected to decline to 0.9x. With earnings unable to cover dividends, Ashmore’s 7.7% dividend yield is at great risk.

Well positioned

MedicX Fund seems like a better buy. The closed-ended investment company focusses on primary healthcare properties (mostly GP practices and pharmacies), and thus benefits from the non-cyclical nature of the healthcare sector.

Shares in the fund currently trade at a 21% premium to its net asset value, which was valued at 70.8p per share at the end of 2015. The fund’s premium may seem expensive, but it is actually lower than the 12-month historical premium of 34%. Still, pessimists would argue that the commercial property sector in the UK is nearing its peak and risks of a cyclical downturn could mean the premium may erode further.

Whilst there are some signs of overheating in the property markets, there are many reasons to be optimistic. The fund is somewhat shielded from any potential downturn, as almost 90% of rental income comes from NHS reimbursable sources and a growing proportion of tenancies have inflation-linked rent review clauses. What’s more, robust growth in healthcare demand and slow supply growth should mean it is well positioned to gain from steadily rising rental income and capital growth.

The fund currently pays a quarterly dividend of 1.475p per share, giving it a 6.9% dividend yield and an underlying dividend cover of 68.0%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended Royal Dutch Shell B. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »